Sino Biopharmaceutical Limited
Sino Biopharmaceutical is a Hong Kong-listed (HKEX: 1177) drugmaker with operations centred in Beijing. Its oncology candidate TQB2102 has an NDA accepted in China, and in October 2026 two more pipeline assets, TQ-A3334 and TQA3605, received breakthrough therapy designations from China's CDE.
| Headquarters | Beijing; Hong Kong, China |
|---|---|
| Listing | HKEX:01177 |
| Lead asset / stage | TQB2102 NDA accepted — China |
| Latest event | TQ-A3334 and TQA3605 received CDE breakthrough therapy designations. |